Arrhythmias and conduction disturbanceRates and Implications for Hospitalization of Patients ≥65 Years of Age With Atrial Fibrillation/Flutter
Section snippets
Methods
This retrospective observational cohort study used data from January 1, 2004, to December 31, 2007, from the United States Thomson Reuters MarketScan Medicare Supplemental and Coordination of Benefits Database. This database contains information on eligible retirees (aged ≥65 years) with Medicare supplemental insurance plans. It includes all employer and Medicare coordination of benefits.7 The United States Thomson Reuters MarketScan databases have been used for numerous health economic and
Results
A total of 55,774 Medicare patients aged ≥65 years with nontransient AF or AFL and no histories of HF were identified from the database population (Figure 1). This represents about 50% of all the patients with AF identified from the Medicare database. The mean postindex follow-up period was 24.3 ± 8.1 months. The mean age was 77.7 years, and 52.2% were men (Table 1). In the 12 months before their index AF or AFL diagnoses, 86.4% of patients had received treatment with antiarrhythmic,
Discussion
This large real-world study demonstrates that Medicare-eligible patients with AF or AFL aged ≥65 years without HF from the MarketScan Medicare Supplemental and Coordination of Benefits Database have a high burden of CV co-morbidities. Most patients receive CV medications, and the use of anticoagulants is particularly common. Patients are frequently hospitalized, with both CV and non-CV diagnoses. Approximately 1/3 of inpatient deaths occur during hospitalizations that have CV primary diagnoses.
References (26)
- et al.
Increasing prevalence of atrial fibrillation and flutter in the United States
Am J Cardiol
(2009) - et al.
Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States
Value Health
(2006) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
A chronic disease score from automated pharmacy data
J Clin Epidemiol
(1992) - et al.
Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?
Am J Med
(2010) - et al.
Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation
Am J Cardiol
(2003) - et al.
Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
JAMA
(2001) - et al.
Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective
J Med Econ
(2008) - et al.
Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective (1992 to 2002)
Stroke
(2006) - et al.
Estimation of total incremental health care costs in patients with atrial fibrillation in the United States
Circ Cardiovasc Qual Outcomes
(2011)
Health research data for the real world: the MarketScan® databases: Thomson Reuters 2009
MarketScan studies, abbreviated bibliography: Thomson Reuters 2009
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation
JAMA
Cited by (38)
The Impact of Age on the Epidemiology and Cost of Atrial Fibrillation Hospitalizations
2023, American Journal of CardiologyChallenges in Assessing the Incidence of Atrial Fibrillation Hospitalizations
2019, Canadian Journal of CardiologyRisk of Hospital Admissions in Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis
2019, Canadian Journal of CardiologyCitation Excerpt :Statistical tests were 2-tailed, and a P < 0.05 was considered to indicate statistical significance. A total of 35 studies including 311,314 patients with AF were included, 32 full-text articles,9,23-54 and 3 abstracts (Fig. 1, Table 1).55-57 Twenty-five articles were prospective studies (13 prospective cohorts and 12 randomized controlled trials) (n = 88,104), and 10 were retrospective cohort studies (n = 223,210).
Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation
2017, Journal of CardiologyCitation Excerpt :The index date was defined as the date of the first anticoagulant prescription following AF diagnosis. Patients with AF enrolled in the MarketScan Medicare Supplemental Database have similar demographic characteristics to patients with AF in the general fee-for-service Medicare population [13,14]. All patient information was Health Insurance Portability and Accountability Act compliant, deidentified, commercially available secondary data; therefore, the Institutional Review Board at the University of Minnesota deemed this analysis exempt from review.
Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study
2017, American Heart JournalCardioversion and subsequent quality of life and natural history of atrial fibrillation
2017, American Heart Journal
Financial support for the development of this report was provided by Sanofi-Aventis U.S., Bridgewater, New Jersey. Editorial support was provided by Jon Edwards, PhD, and was funded by Sanofi-Aventis U.S. Dr. Naccarelli receives research support from GlaxoSmithKline, London, United Kingdom; Boston Scientific Corporation, Natick, Massachusetts; and Boehringer-Ingelheim, Ingelheim, Germany. Dr. Naccarelli is a consultant for Daiichi-Sankyo, Tokyo, Japan; Biosense Webster, Diamond Bar, California; Ortho-McNeil-Janssen, Titusville, New Jersey; Otsuka Pharmaceutical, Tokyo, Japan; St. Jude Medical, St. Paul, Minnesota; Blue Ash Pharmaceutical, Blue Ash, Ohio; Bristol-Myers Squibb, New York, New York; Sanofi-Aventis, Paris, France; Merck, Whitehouse Station, New Jersey; Portola Pharmaceuticals, South San Francisco, California; GlaxoSmithKline; Boehringer-Ingelheim; Pfizer, New York, New York; Medtronic; Gilead Pharmaceuticals, San Dimas, California; Novartis AG, Basel, Switzerland; and Xention, Cambridge, United Kingdom. Mr. Johnston is an employee in the Healthcare Division of Thomson Reuters, which has a research consulting agreement with Sanofi-Aventis. Dr. Dalal is an employee of Sanofi-Aventis U.S. Dr. Lin was an employee of Sanofi-Aventis U.S. when this study was conducted and is currently an employee of Novosys Health, which has a research consulting agreement with Sanofi-Aventis U.S.